The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

Scientists from DZNE, University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease ...

A study by the (UPV/EHU) demonstrates that the drug WIN55,212-2 protects the brain and reverses early cognitive damage caused ...

We all know the occasional feeling of being nervous, shy, or, well, anxious in a social situation, such as when meeting someone new or making a big presentation. That’s normal, and most people ...

Binge eating disorder can seriously affect a person’s physical and mental health. Cognitive behavioral therapy (CBT) is the most effective treatment. Healthcare professionals can prescribe it ...

A treatment that could potentially slow the progression of amyotrophic lateral sclerosis (ALS) is being studied at the Montreal Neurological Institute-Hospital ... “We see very early in the (disease) ...

Epilepsy is one such example. While the seizure disorder was once considered functional, it is now regarded as an organic neurological condition. Determining whether the cause is organic or functional ...

Liam Virgo said having functional neurological disorder (FND) affected his ability to walk and talk and left him "isolated" A man who was left unable to walk or talk by a neurological disorder has ...

A man who was left unable to walk or talk by a neurological disorder has called for greater understanding of his condition after he was told to "get moving" by a GP. Liam Virgo, 22, was 13 when he ...

What Is an Eating Disorder? Eating disorders are a group of conditions marked by an unhealthy relationship with food. They tend to develop during the teenage and young adult years, and they are ...

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.

The deal would allow J&J to gain access to Intra-Cellular's oral therapy, Caplyta, which is approved in the U.S. to treat schizophrenia and depressive episodes associated with bipolar disorder ...